Targeting of interleukin-1 and -18 signaling in treatment of septic shock

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9919048
SERIAL NO

15111374

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITEIT GENTSINT-PIETERSNIEUWSTRAAT 25 GENT 9000
VIB VZWRIJVISSCHESTRAAT 120 GENT 9052

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cauwels, Anje Merelbeke, BE 15 60
Vandenabeele, Peter Sint-Amandsberg, BE 10 174
Vandenberghe, Tom Haasdonk, BE 1 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 20, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 20, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00